Advanced Basal Cell Carcinoma: What Dermatologists Need to Know About Current and Emerging Targeted Therapies

Format: Journal Supplement
Credit(s): 1.00 (60 min)
Release Date: May 13, 2022
Expiration Date: May 13, 2023
Credit Type(s):
  • Physicians – AMA PRA Category 1 Credit(s) ™
  • Physicians/ABIM MOC – ABIM MOC Point(s)
  • Physicians/ABD MOC – ABD MOC Point(s)

PROGRAM OVERVIEW

While most basal cell carcinomas (BCCs) are amenable to surgery or radiotherapy, progression to locally advanced or metastatic BCC is life-threatening, difficult to treat, and not amenable to those standard options. Historically, few treatment options have been available for advanced BCC. The approval of the oral hedgehog pathway inhibitors vismodegib and sonidegib changed the treatment paradigm for patients with locally advanced and metastatic BCC. However, inadequate response or intolerance to these targeted therapies is frequent, leaving an unmet need for many patients with advanced BCC. To meet this need for additional treatment options, the anti-PD-1 therapy, cemiplimab, was recently approved for advanced BCC, and others, i.e. pembrolizumab and nivolumab, are currently in BCC clinical trials.

Advanced Basal Cell Carcinoma: What Dermatologists Need to Know About Current and Emerging Targeted Therapies will provide these clinicians with updates on treatment options, along with reinforcing the roles that dermatologists serve, e.g. monitoring and managing side effects of therapy and ensuring effective multidisciplinary management, in the care of patients with advanced BCC.

PROVIDER

Jointly provided by the Potomac Center for Medical Education and Rockpointe

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

RELATED COURSES

Eosinophilic Granulomatosis with Polyangiitis: Where Are We with Diagnosis and Management?

Learn More

Advances in Skin Cancer Diagnosis: Using New Technologies to Identify High-Risk Patients

Learn More

Nonmelanoma Skin Cancers- Current and Emerging Checkpoint Inhibitors for Treating Advanced Basal Cell and Squamous Cell Carcinomas

Learn More
This entry was posted in . Bookmark the permalink.

Follow Us :

Follow Us :

© 2021 Rockpointe Corporation

Privacy Policy

© 2021 Rockpointe Corporation

Privacy Policy